Reading_Steiner
Senior Member
- Messages
- 245
Easily distracted etc today but I think I sort of get it, you modified the yeasts to make them not be able to do IDO2, and disabled other biomechanics for 'debugging' purpose...they gotta rely on IDO1. They get stuck at high concentration of substrate and they can't lower it for reasons I forgot ( is it like an equilibrium thing ? ) What I didn't understand immediately is how would adding other drugs help, unless they are gonna demethylate IDO1 or IDO2 ( I remembered though the whole point of this trap hypothesis is it doesn't require the persistent viral origin theory of me/cfs ) .
So that means that the potential drug must be doing something to restructure the enzyme to make it work properly in those conditions where it would normally be 'substrate inhibited' ? or is it doing something somewhere else to lower the substrate level ? either reacting with it or facilitating other chemical processes ? but I thought all those other processes were disabled in the yeast, its a little hard to understand.
Could this metabolic trap thing have applications beyond the problem of me/cfs or simply beyond the question of 'is our problem caused by tryptophan / kynurenine levels ' was the concept really never conceived of before ? I'm curious whether the slowed down yeast would respond at all to the drug which your son Whitney was taking ? does it really act at the core pathogenesis or is it just helping in some other way by saving energy, suppressing neuroinflammation or something ? interesting times we are in thankyou Dr Davis & co.
So that means that the potential drug must be doing something to restructure the enzyme to make it work properly in those conditions where it would normally be 'substrate inhibited' ? or is it doing something somewhere else to lower the substrate level ? either reacting with it or facilitating other chemical processes ? but I thought all those other processes were disabled in the yeast, its a little hard to understand.
Could this metabolic trap thing have applications beyond the problem of me/cfs or simply beyond the question of 'is our problem caused by tryptophan / kynurenine levels ' was the concept really never conceived of before ? I'm curious whether the slowed down yeast would respond at all to the drug which your son Whitney was taking ? does it really act at the core pathogenesis or is it just helping in some other way by saving energy, suppressing neuroinflammation or something ? interesting times we are in thankyou Dr Davis & co.